| With coronary artery disease the single leading cause of death in the western
world, aspirin is used by millions of patients as a prevention and treatment
regimen for this deadly disease. In the largest study to date on the
effectiveness of aspirin, researchers at�Sinai
Hospital of Baltimore�recently demonstrated that aspirin resistance is
rare, less than 5 percent, at all doses (81 mg, 162 mg and 325 mg) in patients
with heart disease.
Most coronary artery disease deaths are caused by platelets sticking together
and forming blood clots (thrombosis) that block blood flow within arteries,
resulting in a heart attack. By inhibiting clotting, aspirin keeps platelets
from sticking together by specifically blocking an important enzyme, COX-1.
The occurrence of clotting in patients taking aspirin therapy has been attributed
to the failure of aspirin blocking its target and is a hot topic in cardiovascular
disease today,� said Paul Gurbel, MD, lead investigator for the study and the Helen
Dalsheimer director of the�Division of Cardiology�and director of the�Center for Thrombosis Research at Sinai Hospital of Baltimore.
However, our data suggest that aspirin blocks COX-1 with high
efficiency.�
The team at the Center for Thrombosis Research at Sinai Hospital studied 120
patients with a history of coronary artery disease treated with aspirin. All
patients were randomly placed on 81 mg, 162 mg and 325 mg of aspirin daily for
four weeks each for a total of 12 weeks. Then the response to aspirin was tested
by multitude methods. When measuring the ability of aspirin to block its target,
COX-1, it was found highly effective at all dose levels.
The research also shows that aspirin may be effective at blocking other
pathways that promote platelet activation, independent of COX-1. Further
research is now under way to better understand these additional pathways that
may cause clotting in patients in an effort to continue to improve patient
outcomes,� said Gurbel.
This investigator-initiated study was funded by an unrestricted educational
grant from Bayer HealthCare LLC and Sinai Hospital of Baltimore.
Sinai Hospital of Baltimore is a member of�LifeBridge Health, a regional
health organization, which also includes Northwest Hospital Center,�Levindale Hebrew
Geriatric Center and Hospital,�Jewish Convalescent & Nursing Home, and related
subsidiaries and affiliates.
#�#�#
� | 
